-
Story
Novartis ranks No. 1 in 2026 Access to Medicine Index -
Press Release
Novartis ranks first place in 2026 Access to Medicine Index
-
Story
Fortune includes Novartis in 2026 Change The World List for malaria program -
Press Release
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
-
Press Release
Novartis receives approval for first malaria medicine for newborn babies and young infants
-
Press Release
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
-
Press Release
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
-
Press Release
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
-
Story
Staying one step ahead of the malaria parasite -
Story
Tackling the health toll of climate change -
Press Release
Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
-
Press Release
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment